

**CLAIMS**

---

1-20 (canceled)

21.(previously amended) A method of treating B-cell lymphoma, comprising:

- a) providing:
  - i) a subject having a B-cell lymphoma; and
  - ii) a multivalent(vaccine)comprising at least two recombinant heavy chain variable regions of immunoglobulin molecules derived from said subjects's B-cell lymphoma cells, wherein said at least two recombinant heavy chain variable regions differ by at least one idiotope; and
- b) administering said multivalent vaccine to said subject.

22.(previously amended) The method of Claim 21, wherein said(vaccine)comprises at least two recombinant immunoglobulin molecules comprising said recombinant heavy chain variable regions derived from said lymphoma cells.

C<sup>1</sup>  
23.(previously amended) The method of Claim 21, wherein said(vaccine)further comprises an adjuvant.

24.(previously added) The method of Claim 23, wherein said adjuvant is Syntex adjuvant.

25.(previously added) The method of Claim 21, wherein at least one of said at least two recombinant heavy chain variable regions is conjugated to a carrier protein.

26.(previously added) The method of Claim 25, wherein said carrier protein is KLH.

27-32 (canceled)

---